Gábor Sztaniszláv

Romania could hold a favorable ecosystem for research – development (R&D) in biotechnology, based on a predictable investment framework. “This can be possible by offering tax breaks for investors in this field by encouraging…

„A predictable, coherent and transparent business environment to encourage the investments and stimulate innovation, a stable law framework, funds allotted to the research field are just some of the actions that might contribute to the…

World biotechnology and personlized therapies leader company Amgen, based in USA, is present on the Romanian market for 5 years, with over USD 40 m turnover in 2014, mainly offering targeted therapies in oncology, osteoporosis, rare…